{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T14:39:10Z","timestamp":1788273550403,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","trasci.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.transci.2016.03.002","type":"journal-article","created":{"date-parts":[[2016,3,15]],"date-time":"2016-03-15T07:36:04Z","timestamp":1458027364000},"page":"401-404","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Carfilzomib: A cause of drug associated thrombotic microangiopathy"],"prefix":"10.1016","volume":"54","author":[{"given":"Ibrahim","family":"Qaqish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilana M.","family":"Schlam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harini A.","family":"Chakkera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Adamski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2016.03.002_bib0010","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1055\/s-0032-1333538","article-title":"Evaluation of patients with microangiopathic hemolytic anemia and thrombocytopenia","volume":"39","author":"George","year":"2013","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.transci.2016.03.002_bib0015","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1055\/s-0032-1328886","article-title":"Drug-associated thrombotic microangiopathies","volume":"38","author":"Kreuter","year":"2012","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.transci.2016.03.002_bib0020","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1093\/ndt\/gfs279","article-title":"Thrombotic microangiopathy and associated renal disorders","volume":"27","author":"Barbour","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.transci.2016.03.002_bib0025","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/jca.21276","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue","volume":"28","author":"Schwartz","year":"2013","journal-title":"J Clin Apher"},{"key":"10.1016\/j.transci.2016.03.002_bib0030","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1007\/s12185-008-0140-1","article-title":"Thrombotic microangiopathy after treatment with bortezomib and dexamethasone in a patient with multiple myeloma","volume":"88","author":"Morita","year":"2008","journal-title":"Int J Hematol"},{"key":"10.1016\/j.transci.2016.03.002_bib0035","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1445-5994.2011.02458.x","article-title":"Multiple myeloma presenting with a fever of unknown origin and development of thrombotic thrombocytopenic purpura post-bortezomib","volume":"41","author":"Moore","year":"2011","journal-title":"Intern Med J"},{"key":"10.1016\/j.transci.2016.03.002_bib0040","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.4081\/hr.2012.e13","article-title":"Thrombotic microangiopathy associated with bortezomib treatment in a patient with relapsed multiple myeloma","volume":"4","author":"Salmenniemi","year":"2012","journal-title":"Hematol Rep"},{"key":"10.1016\/j.transci.2016.03.002_bib0045","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2012-006461","article-title":"Bortezomib-induced thrombotic thrombocytopaenic purpura","volume":"2012","author":"Mehta","year":"2012","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.transci.2016.03.002_bib0050","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.3109\/10428194.2014.977887","article-title":"Thrombotic microangiopathy complicating bortezomib-based therapy for multiple myeloma","volume":"56","author":"Chan","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.transci.2016.03.002_bib0055","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2012-10-459883","article-title":"Carfilzomib","volume":"121","author":"Kortuem","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.transci.2016.03.002_bib0060","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","article-title":"Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies","volume":"98","author":"Siegel","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.transci.2016.03.002_bib0065","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/jca.21371","article-title":"Carfilzomib associated thrombotic microangiopathy initially treated with therapeutic plasma exchange","volume":"30","author":"Sullivan","year":"2015","journal-title":"J Clin Apher"},{"key":"10.1016\/j.transci.2016.03.002_bib0070","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/1471-2369-15-156","article-title":"Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma","volume":"15","author":"Hobeika","year":"2014","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.transci.2016.03.002_bib0075","series-title":"vWF multimer assay","year":"2015"},{"key":"10.1016\/j.transci.2016.03.002_bib0080","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","article-title":"Drug-induced thrombotic microangiopathy: a systematic review of published reports","volume":"125","author":"Al-Nouri","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.transci.2016.03.002_bib0085","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/ajh.23960","article-title":"Drug-induced thrombotic microangiopathy: experience of the Oklahoma Registry and the BloodCenter of Wisconsin","volume":"90","author":"Reese","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.transci.2016.03.002_bib0090","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1182\/blood-2008-09-177279","article-title":"Quinine-dependent, platelet-reactive monoclonals mimic antibodies found in patients with quinine-induced immune thrombocytopenia","volume":"113","author":"Bougie","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.transci.2016.03.002_bib0095","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.transci.2016.03.002_bib0100","doi-asserted-by":"crossref","first-page":"794","DOI":"10.7326\/0003-4819-132-10-200005160-00005","article-title":"Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura","volume":"132","author":"Tsai","year":"2000","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.transci.2016.03.002_bib0105","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1038\/ki.2008.613","article-title":"Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989\u20132008)","volume":"112","author":"Zakarija","year":"2009","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.transci.2016.03.002_bib0110","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jca.1013","article-title":"Unintentional platelet removal by plasmapheresis","volume":"16","author":"Perdue","year":"2001","journal-title":"J Clin Apher"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050216000483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1473050216000483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,15]],"date-time":"2022-06-15T04:11:03Z","timestamp":1655266263000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1473050216000483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S1473050216000483"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2016.03.002","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Carfilzomib: A cause of drug associated thrombotic microangiopathy","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2016.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}